ClinicalTrials.gg
CompletedNCT07508228Updated Aug 6, 2026

A Study to Understand How a Study Medicine Called PF-07328948 is Absorbed and Processed in the Body of Healthy Male Adults

A Phase 1 interventional study of Oral [14C]PF-07328948 and Oral Unlabeled PF-07328948 in Healthy, sponsored by Pfizer. Completed at 1 site in United States. Open to male participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-06.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Non-randomized
Ages
18 Years to 64 Years
Sex
Male
01

Study summary

The purpose of this study is to learn how a certain amount of [14C] PF-07320948 is taken up into the bloodstream and removed from the body.

This study is seeking participants who are:

  • Male between 18 to 64 years of age
  • Deemed to be healthy

This is a 2 Part, 4 Period study where Part 1 has Periods 1 and 2 and Part 2, which is optional, has Periods 3 and 4.

Part 1

  • Period 1: The purpose is to see how much of the study medicine PF-07328948 gets into and leaves the body.
  • Period 2: The goal is to compare how much PF-07328948 is available in the body when taken by mouth versus by injection into the blood.

Part 2 (Optional)

  • Period 3 (optional): If needed, the purpose is to see how PF-07328948 acts after taking it daily until the body reaches a steady level.
  • In Period 4 (optional), the goal is to check again how much PF-07328948 is absorbed and leaves the body after daily dosing.

During study clinic stays and study visits, the study team will collect urine and blood samples and perform safety reviews. If only Part 1 is conducted, total time in the study (screening (start) through follow-up (end)) will be about 14 weeks. If both Part 1 and Part 2 are conducted, total time in the study will be about 22 weeks.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male participants aged ≥18 years to \<65 years at screening who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and ECGs.
  • of 17.5-32 kg/m2; and a total body weight >50 kg (110 lb).

Exclusion criteria

Exclusion Criteria

  • Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease.
  • Previous administration of an product (drug or vaccine) within 30 days or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer). Participation in studies of other investigational products (drug or vaccine) at any time during participation in this study.
  • Background radioactivity measured in plasma and/or urine at screening exceeding an F14C value of 2.5.
  • Prior participation in a radiolabeled ADME clinical study within 12 months prior to screening.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Period 1/Treatment A

    Participants will receive a single oral dose of \[14C\]PF-07328948 administered as an extemporaneously prepared oral suspension.

    Drug: Oral [14C]PF-07328948

  • Experimental
    Period 3/Treatment C

    Participants will receive unlabeled tablet oral doses of PF-07328948 once daily for 9 days up to 1 month

    Drug: Oral Unlabeled PF-07328948

  • Experimental
    Period 4/Treatment D

    Participants will receive a single oral dose of \[14C\]PF-07328948 administered as an extemporaneously prepared oral suspension on Day 1; From Day 2 until the last day with mass balance assessment, participants will receive once-daily oral doses of unlabeled PF-07328948 tablets

    Drug: Oral [14C]PF-07328948

  • Experimental
    Period 2/Treatment B

    Participants will receive a single tablet of unlabeled oral dose of PF-07328948; \~ 3 hours post-dose, participants will receive a single IV infusion of \[14C\]PF-07328948

    Drug: Oral Unlabeled PF-07328948 · Drug: IV [14C]PF-07328948

Interventions

  • DrugOral [14C]PF-07328948

    A single oral dose of \[14C\]PF-07328948 administered as an extemporaneously prepared oral suspension in Period 1 and in Period 4 (optional)

  • DrugOral Unlabeled PF-07328948

    A single unlabeled oral dose of PF-07328948 administered as a tablet. Approximately 3 hours post-dose, participants will receive a single IV infusion of \[14C\]PF-07328948 Period 2: single dose, Period 3: QD Period 4: (Day 2 - mass balance completion)

  • DrugIV [14C]PF-07328948

    A single oral dose of \[14C\]PF-07328948 administered as an extemporaneously prepared oral suspension on Day 1; From Day 2 until the last day with mass balance assessment, participants will receive once-daily oral doses of unlabeled PF-07328948 administered as tablets.

06

What researchers measure

Primary outcomes

  1. Total recovery of radioactivity in urine, feces, expired air (if analyzed and if reportable), and emesis (if any), and all routes combined, expressed as a percentage of oral radioactive dose administered.

    Time frame: Period 1 pre-dose to maximum Days 22

Secondary outcomes

  1. Number of Participants with Treatment Emergent Adverse Events

    Time frame: From baseline and through 28 to 35 days post last study intervention dose

07

Study locations

1 site
  • Fortrea Clinical Research Unit Inc.
    Madison, Wisconsin 53704, United States
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2026 to primary completion in Jul 2026, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2026
First posted
Apr 2, 2026
StartActual
Apr 3, 2026
Primary completionActual
Jul 10, 2026
CompletionActual
Jul 10, 2026
Last update
Aug 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07508228
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Apr 2, 2026
Start date
Apr 3, 2026
Primary completion
Jul 10, 2026
Completion
Jul 10, 2026
Last update
Aug 6, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion